- Home
- REVBW vs DUK Comparison
REVBW vs DUK Comparison
Compare REVBW & DUK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REVBW
- DUK
- Stock Information
- Founded
- REVBW N/A
- DUK 1904
- Country
- REVBW United States
- DUK United States
- Employees
- REVBW 9
- DUK N/A
- Industry
- REVBW Biotechnology: Pharmaceutical Preparations
- DUK Railroads
- Sector
- REVBW Health Care
- DUK Industrials
- Exchange
- REVBW Nasdaq
- DUK Nasdaq
- Market Cap
- REVBW N/A
- DUK N/A
- IPO Year
- REVBW 2020
- DUK N/A
- Fundamental
- Price
- REVBW $0.01
- DUK $109.26
- Analyst Decision
- REVBW
- DUK Buy
- Analyst Count
- REVBW 0
- DUK 12
- Target Price
- REVBW N/A
- DUK $122.36
- AVG Volume (30 Days)
- REVBW N/A
- DUK 3.0M
- Earning Date
- REVBW N/A
- DUK 02-13-2025
- Dividend Yield
- REVBW N/A
- DUK 3.82%
- EPS Growth
- REVBW N/A
- DUK 285.29
- EPS
- REVBW N/A
- DUK 5.44
- Revenue
- REVBW N/A
- DUK $29,751,000,000.00
- Revenue This Year
- REVBW N/A
- DUK $7.13
- Revenue Next Year
- REVBW N/A
- DUK $3.64
- P/E Ratio
- REVBW N/A
- DUK $20.09
- Revenue Growth
- REVBW N/A
- DUK 3.48
- 52 Week Low
- REVBW N/A
- DUK $90.09
- 52 Week High
- REVBW N/A
- DUK $121.25
- Technical
- Relative Strength Index (RSI)
- REVBW N/A
- DUK 52.76
- Support Level
- REVBW N/A
- DUK $105.90
- Resistance Level
- REVBW N/A
- DUK $108.59
- Average True Range (ATR)
- REVBW 0.00
- DUK 1.65
- MACD
- REVBW 0.00
- DUK 0.39
- Stochastic Oscillator
- REVBW 0.00
- DUK 86.38
About REVBW Revelation Biosciences Inc. Warrant
Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of therapies for the prevention and treatment of disease using trained immunity. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).